Sodium nucleinate (Tablets, Powder) Instructions for Use
ATC Code
L03AX (Other immunostimulants)
Clinical-Pharmacological Group
Immunomodulator
Pharmacotherapeutic Group
Leukopoiesis stimulator
Pharmacological Action
Sodium nucleinate is isolated from baker’s yeast.
Sodium nucleinate possesses the activity of a polyclonal immunostimulant, regulating the migration of T-lymphocytes and the processes of cooperation between T- and B-lymphocytes, enhances the phagocytic activity of macrophages and the production of factors of nonspecific protection.
It has a wide spectrum of biological activity.
It accelerates tissue regeneration processes, stimulates bone marrow activity and leukopoiesis.
Indications
As part of complex therapy for infectious diseases occurring against the background of secondary immunodeficiency states:
- Chronic nonspecific lung diseases;
- Chronic recurrent viral and bacterial infections;
- Secondary immunodeficiency states associated with aging;
- Correction of leukopenia and agranulocytosis.
ICD codes
| ICD-10 code | Indication |
| A49.9 | Unspecified bacterial infection |
| A60 | Anogenital herpesviral infection [herpes simplex] |
| B00 | Herpesviral [herpes simplex] infections |
| B02 | Zoster [herpes zoster] |
| B19 | Unspecified viral hepatitis |
| B25 | Cytomegaloviral disease |
| D70 | Agranulocytosis |
| D84.9 | Immunodeficiency, unspecified |
| D89 | Other disorders involving the immune mechanism, not elsewhere classified |
| J18.9 | Pneumonia, unspecified |
| J42 | Unspecified chronic bronchitis |
| J44 | Other chronic obstructive pulmonary disease |
| ICD-11 code | Indication |
| 1A94.Z | Anogenital herpes simplex virus infection without further specification |
| 1C41 | Bacterial infection of unspecified site |
| 1D82.Z | Cytomegaloviral disease, unspecified |
| 1E5Z | Unspecified viral hepatitis |
| 1E91.Z | Herpes zoster, unspecified |
| 1F00.Z | Infections due to herpes simplex virus, unspecified |
| 4A0Z | Unspecified primary immunodeficiencies |
| 4B00 | Quantitative defects of neutrophils |
| 4B00.00 | Constitutional neutropenia |
| 4B00.01 | Acquired neutropenia |
| 4B4Z | Diseases of the immune system, unspecified |
| CA20.1Z | Chronic bronchitis, unspecified |
| CA22.Z | Chronic obstructive pulmonary disease, unspecified |
| CA40.Y | Other specified pneumonia |
| CA40.Z | Pneumonia, microorganism not specified |
| MA15.0 | Bacteremia |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Powder
Orally, after meals.
For adults, the daily dose is 1-2 g in 3-4 divided doses.
The course of treatment is 10 days (depending on the severity of the disease – up to 6 weeks).
A course of therapy with the drug (including for the treatment of chronic diseases) can be conducted 2-3 times during the year.
Tablets
Orally, after meals. The daily dose is 1-2 g in 3-4 divided doses. The course of treatment is 10 days (depending on the severity of the disease – up to 6 weeks).
For elderly and senile patients with reduced immune status – 1-1.5 g/day for 2-3 weeks, 2 times a year (in spring and autumn).
For leukopenia in adults – 1 tablet 2-3 times a day, the course of treatment is determined individually, averaging 10 days.
A course of therapy with the drug (including for the treatment of chronic diseases) can be conducted 2-3 times during the year.
Adverse Reactions
Allergic reactions are possible.
Contraindications
- Hypersensitivity to the drug components;
- Pregnancy, lactation period.
Use in Pregnancy and Lactation
Contraindicated during pregnancy and lactation.
Pediatric Use
Not used in children.
Drug Interactions
None identified.
Storage Conditions
In a dry, light-protected place, out of reach of children, at a temperature not exceeding 25°C (77°F).
Shelf Life
Shelf life – 2 years.
Dispensing Status
By prescription.
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Powder for oral administration 0.5 g: bottle 1 pc.
Marketing Authorization Holder
Biosintez, PJSC (Russia)
Dosage Form
| Sodium nucleinate | Powder for oral administration 0.5 g: bottle 1 pc. |
Dosage Form, Packaging, and Composition
| Powder for the preparation of oral suspension | 1 bottle |
| Sodium nucleinate | 500 mg |
500 mg – Bottles with a volume of 10 ml (50) – cardboard boxes.
Film-coated tablets, 250 mg: 10, 20, or 50 pcs.
Marketing Authorization Holder
Biosintez, PJSC (Russia)
Dosage Form
| Sodium nucleinate | Film-coated tablets, 250 mg: 10, 20, or 50 pcs. |
Dosage Form, Packaging, and Composition
| Film-coated tablets | 1 tab. |
| Sodium nucleinate | 250 mg |
Excipients: calcium stearate, potato starch, low molecular weight polyvinylpyrrolidone, refined sugar, aerosil, beeswax, titanium dioxide, food gelatin, basic magnesium carbonate, sunflower oil, paraffin, talc.
50 pcs. – polymer jars (1) – cardboard packs.
